Short-horizon event study estimation with a STAR model and real contaminated events

被引:3
|
作者
Andreou P.C. [1 ,2 ]
Louca C. [1 ,2 ]
Savva C.S. [1 ,3 ]
机构
[1] Department of Commerce, Finance and Shipping, Cyprus University of Technology, 115, Spyrou Araouzou Street, Lemesos
[2] Durham University Business School, Mill Hill Lane, Durham
[3] Centre for Growth and Business Cycle Research, University of Manchester, Manchester
关键词
Contaminated events; Event studies; Markov switching regression model; Smooth Transition Auto Regressive model; Test statistics;
D O I
10.1007/s11156-015-0515-3
中图分类号
学科分类号
摘要
We propose a test statistic for nonzero mean abnormal returns based on a Smooth Transition Auto Regressive (STAR) model specification. Estimation of STAR takes into account the probability of contaminated events that could otherwise bias the parameters of the market model and thus the specification and power of the test statistic. Using both simulated and real stock returns data from mergers and acquisitions, we find that the STAR test statistic is robust to contaminated events occurring in the estimation window and in the presence of event-induced increase in return variance. Under the STAR test statistic the true null hypothesis is rejected at appropriate levels. Moreover, it exhibits the highest levels of power when compared with other test statistics that are widely and routinely applied in short-horizon event studies. © 2015, Springer Science+Business Media New York.
引用
收藏
页码:673 / 697
页数:24
相关论文
共 50 条
  • [21] Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System
    Zhao, Dehua
    Long, Xiaoqing
    Wang, Jisheng
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 599 - 605
  • [22] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
    Guo, Menglin
    Shu, Yamin
    Chen, Guosong
    Li, Juan
    Li, Feie
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [23] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
    Yanchao Yin
    Yamin Shu
    Junru Zhu
    Feie Li
    Juan Li
    Scientific Reports, 12
  • [24] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
    Yang, Yang
    Shu, Yamin
    Chen, Guosong
    Yin, Yanchao
    Li, Feie
    Li, Juan
    PLOS ONE, 2022, 17 (12):
  • [25] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
    Zhang, Xusheng
    Ren, Xiuli
    Zhu, Tianyu
    Zheng, Wanjin
    Shen, Chengwu
    Lu, Cuicui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Real-time preventive sensor maintenance using robust moving horizon estimation and economic model predictive control
    Lao, Liangfeng
    Ellis, Matthew
    Durand, Helen
    Christofides, Panagiotis D.
    AICHE JOURNAL, 2015, 61 (10) : 3374 - 3389
  • [27] Real-time event area localisation and estimation in smart environments based on a realistic sensing model
    Kundu, Srabani
    Das, Nabanita
    Saha, Dibakar
    INTERNATIONAL JOURNAL OF COMMUNICATION NETWORKS AND DISTRIBUTED SYSTEMS, 2021, 27 (04) : 452 - 478
  • [28] Bayesian estimation of group event-related potential components (BEGEP): testing a model for synthetic and real datasets
    Ponomarev, Valery A.
    Kropotov, Jury D.
    JOURNAL OF NEURAL ENGINEERING, 2024, 21 (03)
  • [29] REAL-TIME COMPLETE MODEL ESTIMATION FOR CONTINGENCY STUDY - FIELD EXPERIENCE
    SANDERSON, P
    CURTIS, R
    ATHOW, D
    LU, CN
    LLU, KC
    LETTER, C
    IEEE TRANSACTIONS ON POWER SYSTEMS, 1991, 6 (04) : 1480 - 1484
  • [30] Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
    Li, Yidan
    Sun, Shengzhu
    Wu, Hongyun
    Zhao, Leiyong
    Peng, Wei
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):